Post Profile






Medical News Today: Breast cancer drug shows potential in patients with skin metastases

A study presented at the ESMO Congress reveals how the drug tucatinib led to a reduction in skin metastases for patients with breast cancer.
read more

share

Related Posts


Drug/Chemotherapy Combination Lengthens Survival for Patients with Aggressive Form of Breast Cancer

Health : Newswise Medical News

Treatment combining chemotherapy with two drugs lengthens survival of patients with HER2-positive metastatic breast cancer by an average of nearly 16 months, according to a study led by Sandra M. Swain, MD, medical director, Washing...

Optimal Duration Of Trastuzumab Therapy For Women With HER2+ Early Breast Cancer: New Findings

Health : Medical News Today

New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. "These long awaited ...

The First Ever Estimate Of The Economic Burden Of Cancer In Europe Shows That It Exceeds 124 Billion Euros

Health : Medical News Today

New studies that reveal for the first time the real economic and human costs of caring for cancer patients in Europe will be presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. "Here we ha...

Shortcomings In Patient Care For Elderly Breast Cancer Patients

Health : Medical News Today

A study led by Professor Christos Markopoulos from Athens University Medical School in Athens, Greece presented at the 2011 European Multidisciplinary Cancer Congress, shows that women diagnosed with breast cancer late in life have ...

Breast Cancer Patients Live Nearly Six Months Longer With New Precision Drug Compared To Current Treatment Option

Health : Medical News Today

Data from the Phase III EMILIA study, presented at the European Society for Medical Oncology (ESMO) show that T-DM1 (trastuzumab emtansine) prolongs the lives of patients with advanced HER2-positive breast cancer when compared with ...

Comments


Copyright © 2016 Regator, LLC